# The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors

> **NCT05821751** · NA · UNKNOWN · sponsor: **Fondazione del Piemonte per l'Oncologia** · enrollment: 40 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DIETARY_SUPPLEMENT:** inulin
- **DRUG:** Pembrolizumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05821751
- **Lead sponsor:** Fondazione del Piemonte per l'Oncologia
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-02
- **Primary completion:** 2024-12-02
- **Final completion:** 2025-12-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05821751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05821751, "The Effect of Prebiotic Inulin on Patients Affected by R/M HNSCC Treated With Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT05821751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*